Pulmonary Hypertension

Clinical Centers


Mission Statement:

Pulmonary hypertension (PH) is a complex disorder with significant effects on morbidity and mortality. It is of paramount importance to gain greater understanding of the mechanisms responsible for disease pathogenesis in these patients to provide more comprehensive treatment options. The mission of the Pulmonary Hypertension Center at Boston Medical Center (Boston University School of Medicine) is to improve the lives of persons living with pulmonary hypertension by providing state-of-the-art patient care coupled with innovative research aimed at understanding the pathogenesis and natural history of pulmonary hypertension.

Background:

The staff of the Pulmonary Hypertension Clinic at Boston Medical Center is comprised of two physicians and one nurse practitioner with expertise in pulmonary hypertension and a dedicated clinic staff. The clinic is directed by Harrison W. Farber, Professor of Medicine at Boston University School of Medicine and an acknowledged expert in the diagnosis, treatment, and investigation of pulmonary hypertension. Dr. Farber’s areas of clinical focus include patients with pulmonary hypertension related to systemic sclerosis and HIV disease. Dr. Klings, an Assistant Professor of Medicine at Boston University School of Medicine, has expertise in the care of patients with pulmonary hypertension related to sickle cell disease and is currently lead author on the soon to be published Clinical Guidelines for Diagnosis and Treatment of Pulmonary Hypertension of Sickle Cell Disease. Both Drs. Klings and Farber are active members of the Pulmonary Hypertension Association and each of them lectures locally, nationally and internationally on the care of PH patients.

Patients with PH are referred to the Pulmonary Hypertension Clinic from both within Boston Medical Center as well as from throughout New England. Some patients come only for an initial evaluation or second opinion, while others may be followed for years. Approximately 150-200 new referrals per year are seen at the Pulmonary Hypertension Clinic. Right heart catheterizations are performed routinely in the Cardiac Catheterization Laboratory at the Newton Pavilion of Boston Medical Center by Drs. Farber and Klings with our clinical fellows. We perform approximately 250 right heart catheterizations annually.

Clinical Activities:

  • Initial assessment of patients with pulmonary hypertension
  • Diagnostic right heart catheterizations with vasodilator trials
  • Use of oral, inhaled and systemic pulmonary vasodilator therapy when indicated
  • Ongoing treatment for pulmonary hypertension including clinical follow-up with 6 minute walk tests, repeat echocardiography and right heart catheterizations, and referral for lung transplant as needed
  • Participation in clinical trials and on-going Investigator-initiated research with the goal of advancing knowledge about the pathogenesis and treatment of pulmonary hypertension

Research Activities:

  • See Pulmonary Hypertension – Clinical and Translational Research and Vascular Biology websites.

Investigators/Personnel:

  • Harrison W. Farber, MD, Professor of Medicine
  • Director, Pulmonary Hypertension Center
  • Elizabeth S. Klings, MD, Assistant Professor of Medicine
  • Denise Brett-Curran, RNP
  • Kim Tobin-Finch, RN
  • Fei-Ying Cheong, Research Coordinator

Selected Publications:

  1. Farber HW, Foreman AJ, Miller DP, McGoon MD. REVEAL registry: Correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension. Congest Heart Fail. 2011 Mar-Apr;17(2):56-64.
  2. Klings ES, Machado RF, Barst RJ, Morris CR, Mubarek K, Gordeuk VR, Kato GJ, Ataga KI, et al. An Official ATS Clinical Practice Guideline: Diagnosis and Treatment of Pulmonary Hypertension of Sickle Cell Disease. Am J Resp Crit Care Med 2011 (manuscript under review).
  3. Brown LM, Chen H, Halpern S, Taichman D, McGoon MD, Farber HW, Frost AE, Liou TG, Turner M, Feldkircher K, Miller DP, Elliott CG. Delay in recognition of pulmonary arterial hypertension: Factors identified from the REVEAL registry. Chest. 2011 Jul;140(1):19-26.
  4. Hawkins F, Ebel N, Sorescu GP, McMahon L, Sprinz P, Klings ES. Keeping It In the Family – Three Relatives with HbSC Disease and Simultaneous Acute Pulmonary Emboli. 2011 Am J Hematology (in press).
  5. Walkey AJ, Fein D, Horbowicz KJ, Farber HW. Differential response to intravenous prostacyclin therapy in patients with pulmonary arterial hypertension. Pulm Pharmacol Ther. 2011 Aug;24(4):421-5.
  6. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009 Apr 28;53(17):1573-619.
  7. Oudiz RJ, Farber HW. Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J. 2009 Apr;157(4):625-35.
  8. Klings ES, Bland DA, Rosenman D, Princeton S, Odhiambo A, Li G, Bernard SA, Steinberg MH, Farber HW. Pulmonary Arterial Hypertension and Left-Sided Heart Disease in Sickle Cell Disease: Clinical Characteristics and Association with Soluble Adhesion Molecule Expression. Am J Hematol 2008 83 (7):547-553.

For Patients

To schedule a clinic visit, refer a patient, or speak with one of our physicians, please contact us at:

Boston Medical Center
Pulmonary, Allergy & Sleep
Shapiro Center
9th Floor, Suite 9B
725 Albany Street
Boston, MA 02118
(617)638-7480
Fax: (617) 638-7486